Can blood gene expression predict which patients with multiple sclerosis will respond to interferon?

Fig 1. Hierarchical clustering of genes detected as differentially expressed in rapid versus slow progression PD patients. Classification based on expression signals of

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease

Clinical response to interferon beta and glatiramer acetate in multiple sclerosis patients: a Brazilian cohort.. Resposta terapêutica ao interferon beta e ao acetato de glatiramer

Expression and activation by Epstein Barr virus of human endogenous retroviruses-W in blood cells and astrocytes: inference for multiple sclerosis. Sanadgol N, Ramroodi N, Ahmadi

between polymorphism in the IL7R a (rs6897932C) gene, HLA-class II DRB1* haplotypes and susceptibility to multiple sclerosis in patients. with Recurrent Remitting

Detection of olfactory dysfunction using olfactory event related potentials in young patients with multiple sclerosis. DeLuca GC, Joseph A, George J, Yates RL, Hamard M, Hofer M

Past exposure to sun, skin phenotype, and risk of multiple sclerosis: Case-control study. Ristori G, Cannoni S, Stazi MA, Vanacore N, Cotichini R, Alfò M

Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod